Sürdürülebilir Kalkınma Amaçları

• 2

• MakaleAçık Erişim2026/r/kostu/10843
  How does colchicine use affect neutrophil/lymphocyte, monocyte/lymphocyte, and platelet/lymphocyte ratios in coronary artery disease?

  Öztürk, Fatih; Yaman, Mehmet

  Objective: It is an established medical fact that the reduction of inflammation plays a pivotal role in the development of atherosclerosis. This reduction of inflammation is an accepted treatment strategy for coronary artery disease (CAD). The objective of the present study was to demonstrate the effect of colchicine, a commonly used anti-inflammatory agent, on inflammatory markers. Method: The study comprised a sample of 122 patients diagnosed with CAD, whose medical records were meticulously reviewed. Ratios of neutrophil/lymphocyte, monocyte/lymphocyte, and platelet/lymphocyte were calculated and recorded. Following a period of six months during which colchicine was administered, a recalculation of the values was performed. Results: Prior to the commencement of treatment, the neutrophil/lymphocyte ratio (NLR) (3.99 ± 4.72), monocyte/lymphocyte ratio (MLR) (0.41 ± 0.42), and platelet/lymphocyte ratio (PLR) (129.6 ± 74.1) were observed. Following treatment, a decrease was observed in the neutrophil-to-lymphocyte ratio (NLR) (3.5 ± 3), MLR (0.38 ± 0.28), and PLR (122.6 ± 65). In the post-treatment period, statistically significant decreases were observed NLR, MLR, and PLR compared to pre-treatment levels (p<0.001 for all values). Conclusion: In the present study, a significant decrease in the levels of NLR, MLR and PLR was observed in patients with CAD following the initiation of colchicine treatment.

  • 
  İncele
• MakaleAçık Erişim2026Scopus SJRQ2/r/kostu/10220
  Effect of sacubitril/valsartan and SGLT2 inhibitors on arrhythmia burden in ICD patients

  Öztürk, Fatih; Yaman, Mehmet

  Background: This study aimed to examine whether the use of sodium–glucose co-transporter 2 inhibitors (SGLT2i) and/or sacubitril/valsartan in individuals with an implantable cardioverter-defibrillator (ICD) was associated with differences in pathological rhythm burden, specifically atrial fibrillation (AF), ventricular tachycardia (VT), and ventricular fibrillation (VF), during follow-up. Methods: Data from 275 patients who underwent ICD implantation between 2022 and 2025 were analyzed retrospectively. The primary endpoint was change in device-detected arrhythmic burden, categorized as unchanged/increased, 0–50% reduction, 50–100% reduction, or arrhythmia-free status during 12-month follow-up. The secondary endpoint was change in LVEF (ΔEF). Associations between medical therapies and EF change were assessed using multivariable linear regression models adjusted for demographic and clinical covariates. Results: Overall, mean LVEF increased significantly during follow-up (ΔEF 9.7 ± 8.7%, p < 0.001). In adjusted analyses, ARNI use was independently associated with greater EF improvement (B = 10.647, p < 0.001), whereas SGLT2i therapy alone was not significantly associated with ΔEF. In unadjusted analyses, both ARNI and SGLT2i therapies were associated with a higher likelihood of substantial reduction in arrhythmic burden and arrhythmia-free status (p < 0.001 for both). Patients receiving combined ARNI and SGLT2i therapy demonstrated the highest proportion of arrhythmia-free status during follow-up. Conclusion: In this retrospective cohort of ICD recipients with HFrEF, ARNI therapy was independently associated with greater improvement in LVEF, while both ARNI and SGLT2i use were associated with lower device-detected arrhythmic burden in unadjusted analyses. Prospective studies are required to determine causality and clarify the independent antiarrhythmic effects of contemporary guideline-directed therapies in ICD populations.

  • 
  İncele